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Possible approaches to screening, assessment and integrated  
treatment planning by service setting 
Treatment setting High prevalence 
of co-occurring… 
Screening Assessment Integrated Treatment 
Planning 
 
A 
O 
D 
AOD 
• Anxiety & depression  
• Post traumatic stress 
disorder (PTSD) 
• Personality disorder 
• Risk 
• K10 
• PsyCheck 
• MH screening form 
• MINI 
Low threshold for referral to 
Mental Health for risk 
assessment/management 
AOD clinician or team 
addresses both disorders OR 
agrees & implements an 
individual treatment plan with 
mental health 
PDRSS • All substances • ASSIST In-house OR with clinical mental health or AOD 
CAMHS/ 
Early Psychosis 
• All substances 
• Cannabis 
• Alcohol 
• Ongoing screening/ high 
index of suspicion  
• ASSIST for all people 13-
years & older  
• Sensitive questioning for 
younger people  
In-house, integrated AOD 
assessment in response to 
positive AOD screen 
Adult  
Community 
 
• All substances  
 
• ASSIST 
In-house, integrated AOD 
assessment in response to 
positive AOD screen 
Adult  
Inpatient 
• All substances  
• Substance withdrawal • ASSIST 
• If positive ASSIST 
response  
• Withdrawal scales 
Aged • Alcohol • Prescription meds abuse 
• AUDIT 
• ASSIST 
• Sensitive questioning re 
prescription drugs 
Full AOD assessment if 
positive AUDIT or ASSIST 
response 
MH clinician or team 
addresses both disorders OR 
agrees & implements an 
individual treatment plan  with 
AOD service 
 
‘Integration needs to continue 
beyond acute intervention & 
through recovery by way of 
formal interaction & co-
operation between agencies in 
reassessing & treating the 
client’ DHS 2007 
 
 
M 
e 
n 
t 
a 
l 
 
H 
e 
a 
l 
t 
h 
Primary  
Mental Health 
• Alcohol abuse 
• Alcohol dependence 
• AUDIT 
• ASSIST 
 
 
Full AOD assessment if 
positive AUDIT or ASSIST 
response 
• BI’s for harmful use  
• Attempt referral 
to/collaborative work with 
AOD if meets criteria for 
dependence  
Guideli
Screening and Assessment of Co-occurring Substance Use and Mental Health 
Disorders 
How to use this guide 
 
Evidence shows that people with mental health or substance use disorders are at 
increased risk of also developing the other disorder. Early recognition of co-
occurring disorders leads to the development of the most effective possible 
treatment. Yet even very experienced mental health clinicians often fail to recognise 
a co-occurring substance use disorder. Similarly, many substance use disorder 
treatment clinicians struggle to recognise – let alone assess and respond to – the 
presence of co-occurring mental health disorders in their clientele.  
 
This guide aims to equip treating mental health (MH) and alcohol and other drug 
(AOD) treatment clinicians and agencies to recognise co-occurring disorders and 
provide effective responses.  
 
The section Screening and assessment in practice provides guidelines for 
screening and assessment in practice, and addresses the main challenges 
confronting clinicians and managers seeking to implement routine screening in MH 
or AOD treatment settings. These include: why, who, how and when screening 
should take place; when not to screen; the difference between assessment and 
screening for co-occurring disorders; barriers to routine integrated screening, 
assessment and treatment; issues in screening with younger people; and steps to 
take after screening has occurred. 
 
Screens for mental health symptoms and disorders outlines four key tools 
available for use in screening for mental health symptoms and disorders and is 
aimed at clinicians currently working in the Victorian AOD sector. These include: 
• K10 
• PsyCheck 
• Modified Mini Screen 
• Mental Health Screening Form. 
 
Screens for substance use disorders introduces Victorian MH clinicians to four 
key tools that may be used when screening for substance use disorders. These 
include: 
• Sensitive questioning 
• AUDIT 
• ASSIST 
• Cage / CageAid. 
 
Screening tools are generally available online. The table on page iii of this guide 
provides an overview of the range of possible approaches to screening, 
assessment and integrated treatment planning by service setting and how 
screening tools may be used. 
 
These guidelines provide only a brief profile of some of the available tools and 
approaches supported by the Victorian Dual Diagnosis Initiative (VDDI). Readers 
wishing for more detailed information will find a wealth of valuable resources listed 
in the References section of this guide. Also included are sample proformas and 
protocols for use by clinicians and agencies, and contact details for the Victorian 
Dual Diagnosis Teams. These teams role includes assisting with complex dual 
diagnosis presentations in collaboration with senior clinical staff or case managers 
and assisting individual services to plan how they will establish quality dual 
diagnosis practices within their services and meet the requirements of the state-
wide Dual Diagnosis Action Plan 2007-2010. 
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Screening and Assessment of Co-occurring Substance Use and Mental Health 
Disorders 
Key directions and priorities for Victorian services 
 
The Victorian Department of Human Services 2007 policy Dual diagnosis: Key 
directions and priorities for service development outlines key directions and 
priorities for Victorian dual diagnosis service development.  
 
• Dual diagnosis is systematically identified and responded to in a timely, 
evidence-based manner as core business in mental health and AOD 
services.  
• All clients to be screened for co-occurring disorders by 2008. 
• By 2010 all positive screens should trigger a full assessment of likely co-
occurring disorders.  
• All mental health and AOD workers to be dual diagnosis capable by 2010.  
• Dual diagnosis capability is defined as able to screen and assess co-
occurring disorders. Advanced practitioners will also be able to treat co-
occurring disorders. 
 
Implications for clinicians and services 
 
A pivotal strategy in the Victorian DHS policy has been the attribution of primary 
responsibility for achieving the mandated Service Delivery Outcomes to mental 
health and AOD service managers. These guidelines have been drafted to: 
 
• Assist busy managers to achieve the screening and assessment goals 
mandated in the DHS Victorian Service Delivery Outcomes. 
• Enable clinicians and their services to recognise and respond to co-
occuring disorders. 
• Improve effectiveness of treatment for ‘target’ disorders. 
• Provide tools and possible strategies/approaches for routine detection, 
assessment and integrated treatment planning in both mental health and 
AOD services. 
• Improve detection of common co-occurring disorders and increase the 
likelihood of earlier intervention with lower input, more effective treatments. 
 
It is not intended that either mental health or AOD services should vary their primary 
criteria for entry to their service system. Rather that, where people who do meet 
criteria for their services also have a co-occurring disorder, this will be routinely 
detected and assessed, and an Integrated Treatment Plan developed that responds 
to both mental health and substance use disorder treatment needs. 
 
Where workers encounter a person who does not meet the criteria for service from 
their agency, they should work with that person to establish where they are likely to 
get the most useful service and to actively assist the person to obtain that service. 
This is what’s known as a ‘no wrong door’ service system (DHS, 2006). 
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 Introduction 
 
Internationally, the past two decades has seen substantial interest and 
investment in resolving the question of how treatment systems can deliver more 
effective treatment to people presenting with both a mental health and a 
substance use disorder. This question has occupied researchers, clinicians, 
service managers, central planning and policy bodies in primary care, mental 
health and drug treatment settings.  
 
It has been driven by the compelling evidence around two key areas: 
• the prevalence of co-occurring disorders in mental health and drug 
treatment settings – they are the ‘expectation not the exception’ (Minkoff 
and Cline, 2004) 
• the harms strongly associated with having both disorders compared to 
having only one of the disorders. 
 
It has received further impetus from: 
• growing consumer and carer demand 
• the potential for both AOD and mental health treatment sectors to be 
more effective in treating their target disorders by increasing their 
recognition of, and developing their response to, co-occurring mental 
health and substance use disorders. 
 
Dual diagnosis – the expectation not the exception 
People presenting with co-occurring mental health and substance use disorders 
are the ‘expectation not the exception’ in both drug treatment and mental health 
settings – albeit often with different predominant mixes of disorders, severity and 
treatment needs in either sector.  
 
When an individual experiences both a mental health and a substance use 
disorder, the disorders tend to influence each other in their development, their 
severity, their response to treatment and their relapse circumstances (Croton, 
2005). If a clinician attempts to treat either disorder without recognising and 
responding to the co-occurring disorder, the treatment of the ‘target’ disorder is 
likely to be less effective. Recognising and responding to co-occurring disorders 
is likely to improve the effectiveness of treatment of ‘target’ disorders. 
 
A range of factors may contribute to clinicians failing to recognise co-occurring 
disorders. Both substance use and mental health disorders are often not 
immediately evident, especially when they are high-prevalence, low-impact 
type disorders. A dedicated effort by an assessing clinician may be required in 
order to establish whether a co-occurring disorder exists. As both disorders are 
so highly stigmatised, a person receiving assessment may be reluctant to 
disclose information indicative of a co-occurring disorder. Substance use 
treatment or mental health clinicians may lack confidence in their ability to provide 
treatment for a co-occurring disorder and hence be reluctant to ask questions that 
could detect that disorder.  
 
Regardless of the reason for service systems or clinicians not recognising co-
occurring disorders, the implementation of a routine screening protocol will 
increase the likelihood of treatment-impacting co-occurring disorders being 
detected and responded to. In those cases where the clinician lacks the skills, 
training or time to assess for a particular co-occurring disorder, use of a validated 
screening tool will increase case detection and enhance treatment planning. The 
recognition of a co-occurring disorder is a necessary prelude to assessment of 
the disorder in order to inform the development of an Integrated Treatment Plan 
(see Appendix 4) that addresses both disorders. 
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 The importance of screening for co-occurring disorders 
 
Globally, there is substantial anecdotal and research evidence and concern about 
people with co-occurring disorders tending to ‘fall between the gaps’ – their co-
occurring disorder going unrecognised and hence failing to receive treatment 
from either service system (Senate Select Committee on Mental Health, 2006). 
There is good evidence that even very experienced mental health clinicians may 
often fail to recognise the presence of a co-occurring substance use disorder (Ley, 
Jeffery, Ruiz, McLaren & Gillespie, 2002; Barnaby, Drummond, McCloud, Burns 
& Omu, 2003; Ries, Dyck, Short, Srebnik, Snowden & Comtois, 2002). Similarly, 
many substance use treatment clinicians may struggle to recognise, let alone 
assess and respond to, the presence of co-occurring mental health disorders in 
their clients. While much is still to be learned about what constitutes effective 
treatment, there is general agreement that, in order to provide any treatment, it is 
first necessary for treating clinicians and agencies to recognise that a co-
occurring disorder exists.  
 
The case for routine screening in Victorian services 
 
Both mental health and substance use disorders may be broadly divided into 
high-prevalence/lower-impact disorders or low-prevalence/higher-impact 
disorders (Table 1). As a general rule the treatment of high-prevalence/low- 
impact-type disorders is likely to be more effective, with lower inputs, than the 
treatment of low-prevalence/high-impact-type disorders. However high-
prevalence/low-impact-type disorders are often less visible and more difficult to 
detect – especially when there is not a screening protocol or tools to support the 
detection and assessment of co-occurring disorders.  
 
      Mental health disorder Substance use disorder 
High-prevalence/ 
low-impact disorders 
- Anxiety 
- Depression 
- Harmful use (ICD10)  
- Abuse (DSM-IV) 
Low-prevalence/ 
high-impact disorders 
- Psychosis 
- Major mood disorder 
- Dependence (ICD & 
DSM) 
Table 1: High-prevalence/low-impact and low-prevalence/high-impact mental health 
and substance use disorders 
 
As you’d expect, the actual numbers of people with high-prevalence/low- 
impact-type disorders are greater than the actual numbers of people with low-
prevalence/ high-impact-type disorders.  
 
The exciting and large-scale potential human and financial savings that may be 
achieved with low-cost interventions with people who have the high-
prevalence/low-impact-type disorders are dependent on increasing our 
recognition of these disorders. Routine screening for co-occurring disorders of 
people who present to either mental health or AOD agencies is likely to contribute 
substantially to improved detection of common co-occurring disorders, and 
increases the likelihood of earlier intervention with lower-input, more effective 
treatments. 
 
These are some of the reasons why a guiding principle of routine screening for 
co-occurring disorders by mental health and substance treatment agencies is 
evolving in a number of treatment systems around the world.  
 
Treatment systems are attempting to improve the effectiveness of their response 
to co-occurring substance use and mental health disorders (dual diagnosis) 
because of:  
• prevalence – the ‘expectation not the exception’ in treatment settings 
• harms associated with having both disorders 
• consumer and carer demand 
• potential to be more effective in treating ‘target’ disorders.  
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Research indicates that integrated treatment of co-occurring disorders will often 
be more effective than non-integrated treatment. The Victorian Department of 
Human Services 2007 policy Dual diagnosis: Key directions and priorities for 
service development defines integrated treatment as occurring when a clinician 
or treating team within the one service addresses both a person’s substance use 
& mental health problems. The policy states that integrated treatment can also 
occur when staff of separate agencies work together to agree and implement an 
individual treatment plan. It notes that ‘integration needs to continue beyond 
acute intervention & through recovery by way of formal interaction & co-operation 
between agencies in reassessing & treating the client’ (DHS 2007). Different 
service settings and clinicians will have differing capacities to provide integrated 
treatment to the various possible combinations of disorders that people will 
present with. 
 
Screening may contribute to the development of a common language and 
understanding between mental health and AOD treatment agencies. Where 
agencies have collaborated on selection of screening tools, joint training in their 
use and agreed protocols around responses to and priority of positive screens, 
there may be less potential for interagency tensions and disappointments and 
greater potential for the provision of effective integrated treatment.  
 
A potentially substantial gain, likely to be derived from implementing routine 
screening for co-occurring disorders, is that earlier, low-input, more effective 
treatment interventions are made possible as the disorders are recognised at an 
earlier stage, before they have become established and collateral damage, losses 
and dependence have occurred.  
 
Screening is part of assessment 
 
Screening is a component of an assessment. A screen is only a brief method of 
determining whether a particular condition is present. A positive screen should 
trigger a detailed assessment that will confirm whether the condition or disorder is 
indeed present. In turn, assessment of both disorders will inform and develop 
integrated treatment planning for all detected disorders. 
 
The aim of screening is to increase the detection of co-occurring disorders and to 
indicate when a detailed assessment of co-occurring disorders is warranted. The 
aim of assessment of co-occurring disorders is to garner information that will 
inform effective integrated treatment planning.  
 
In practice, the distinction between screening and assessment is not and should 
not be clear-cut. Many screening tools also provide useful assessment 
information. Once a clinician has incorporated routine screening into their practice 
the transition from screening to assessment will be imperceptible to the client. 
Screening processes, sensitively deployed, provide a further opportunity to build 
engagement with clients. 
 
A guiding principle of routine screening for co-occurring disorders by mental 
health and substance treatment agencies has evolved because: 
• often co-occurring disorders are not recognised, even by experienced 
clinicians 
• under-recognised, under-treated co-occurring disorders reduce the 
effectiveness of the treatment of ‘target’ disorders 
• there is potential for large-scale human and financial savings in 
increasing our recognition of and developing our response to co-
occurring disorders 
• there is a need to improve the effectiveness of responses to high-
prevalence disorders (anxiety, depression, and hazardous rather than 
dependent  substance abuse).  
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 Screening of young people 
 
Both mental health and substance use disorders are highly prevalent among 
young people. One in ten young people aged 15–17 have a mental health 
disorder (AIHW, 2006)  Around a quarter of young people aged 12–14 years drink 
alcohol to some extent (AIHW, 2006). By age 15, nearly a third of Australian 
children report binge drinking (5 or more drinks on a single occasion) within the 
past fortnight (Murdoch Children’s Institute, 2007).  
 
Compared to adults, younger people will tend to: 
• be more likely to see substance use as a solution rather than a problem 
• be more likely to be experimenting with a range of substances 
• be less likely to meet the criteria for substance dependence (however will 
frequently meet the criteria for harmful use – see Appendix 5). 
 
Issues around screening for co-occurring substance use or mental health 
disorders in young people include:  
• confidentiality and disclosure 
• the age at which screening should be instituted 
• screening approaches. 
 
The international context 
 
In the USA, the federal Substance Abuse Mental Health Services Administration 
(SAMHSA) includes in their 2006/2007 strategic plan a measure to ‘Increase the 
percentage of prevention and treatment settings that: 
• screen for co-occurring disorders  
• assess for co-occurring disorders’ 
 
Minkoff and Cline developed the influential Comprehensive Continuous 
Integrated System of Care (CCISC) model for organising services for individuals 
with co-occurring psychiatric and substance disorders. The model is designed to 
improve treatment capacity for these individuals in systems of any size and 
complexity, ranging from entire states to regions or counties, networks of 
agencies, individual complex agencies, or even programs within agencies.  
One of the strategies of the CCISC model for addressing co-occurring disorders 
is to establish policies and procedures for universal screening for co-occurring 
disorders at initial contact throughout the system. CCISC is being deployed in a 
number of sites in the USA and Canada.  
 
The Australian context 
In New South Wales, the Mental Health Outcomes and Assessment project (MH-
OAT) has implemented uniform assessment protocols across the state in order to 
strengthen the mental health assessment skills of clinical staff. The NSW 
standardised CAMHs, Adult and Aged mental health assessment forms all 
contain a reasonably detailed substance use assessment that clinicians are 
mandated to use with people receiving mental health assessment. 
 
The Victorian Department of Human Services 2007 policy Dual diagnosis: Key 
directions and priorities for service development mandates that:  
 
‘Dual diagnosis is systematically identified and responded to in a 
timely, evidence-based manner as core business in mental health 
and AOD services. A priority is to establish mechanisms and processes 
that ensure that dual diagnosis is systematically recognised and 
assessed in both mental health (clinical and PDRSS) and alcohol and 
other drug services. A screening approach should be incorporated in 
early assessment activities that provides sufficient information to identify 
the need for further more detailed assessment’. 
 
 
 Page 4
 Developing capacity in Victoria 
The Victorian dual diagnosis policy sets out the expectation that all Victorian 
mental health and drug treatment staff are ‘dual diagnosis capable’.  
 
Dual diagnosis capability is defined as: 
• At the most basic level – to be able to administer a screening tool 
appropriate to their service age group, undertake a dual diagnosis 
assessment, and consult others with more advanced knowledge and 
skills in making decisions about the most appropriate course of action to 
be taken. 
• At the advanced level – to be able to both assess and effectively treat 
co-occurring disorders within service and practice guidelines. 
 
A pivotal strategy in the Victorian DHS policy has been the attribution of primary 
responsibility for achieving the mandated Service Delivery Outcomes to mental 
health and AOD service managers.  
 
 
 
What’s next after screening? 
 
Once a co-occurring disorder has been detected, the challenge facing mental 
health and AOD services and clinicians is to decide how best they can achieve 
integrated treatment of both disorders. Is it within the clinician’s or their agency’s 
capacity to provide integrated treatment of both disorders? If not, what is the most 
efficient means of engaging another service in the development of a single 
Integrated Treatment Plan addressing both disorders? 
 
Three key concepts can assist in the development of the most effective possible 
responses to the various treatment needs of people with co-occurring disorders: 
 
1. Cohorts of people with co-occurring disorders within the service 
system– the Victorian dual diagnosis policy proposes a three-level 
schema that attributes responsibility for providing treatment to the various 
cohorts of people with dual diagnosis to different sectors of the service 
system – primary care, specialist AOD or specialist mental health 
services.  
 
2. Integrated treatment – the available evidence indicates that integrated 
treatment of co-occurring disorders often tends to be more effective than 
non-integrated treatment for many people with dual diagnosis. 
 
3. ‘No wrong door’ service system goals – all people with co-occurring 
disorders are actively and meaningfully assisted to obtain appropriate 
treatment from within the service system by the service to which they 
present, even if they don’t meet that service’s criteria for treatment. 
 
These three concepts are explored in detail in the After screening – the next 
steps section of these guidelines.  
 Page 5
 Guiding principles 
A set of principles has evolved to guide mental health and substance use disorder 
treatment clinicians and agencies in routinely screening for co-occurring disorders. 
 
• All people receiving mental health or substance use treatment should be 
screened or assessed for a co-occurring disorder. An exception may be 
young people under the age of 13. 
 
Routine screening represents an efficient method for services to increase 
their recognition of co-occurring disorders, where they do not possess the 
necessary expertise, supports or time to routinely, adequately, assess co-
occurring disorders. However, screening is not necessary where 
comprehensive routine dual diagnosis assessment is provided. 
 
• Screening and/or assessment for a co-occurring disorder should take place 
at or near a person’s first contact.  
 
Early detection and assessment of co-occurring disorders contributes to 
effective, targeted treatment planning. 
 
• Screening and assessment should not be attempted when the client is 
intoxicated, distressed, in pain, in need of emergency treatment or acutely 
psychotic. 
 
• Younger people should receive some level of screening for a co-occurring 
disorder at each contact. 
 
• All people with co-occurring disorders should be actively and meaningfully 
assisted to obtain appropriate treatment from within the service system by 
the service to which they present, even if they don’t meet that service’s 
criteria for treatment (the ‘no wrong door’ service system approach). 
 
• Where possible, clients should receive integrated treatment of co-occurring 
mental health and substance use disorders. 
 
 
Integrated treatment occurs when a clinician provides treatment for both a 
client’s substance use and mental health problems. Integrated treatment also 
occurs when staff of separate agencies work together to agree and 
implement an individual treatment plan. This integration needs to continue 
beyond acute intervention & through recovery by way of formal interaction & 
co-operation between agencies in reassessing & treating the client. 
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 Screening and assessment in practice 
This section addresses some of the questions clinicians and managers may face 
when incorporating routine screening into their own or their agency’s practice, 
whether in MH or AOD treatment settings. 
 
What is the difference between screening and 
assessment? 
 
 
Screening is a component of an assessment. A screen is a brief method of 
determining whether a particular condition (such as domestic violence) or disorder 
(such as substance use or mental health) may or may not be present. A positive 
screen will usually trigger a more detailed assessment of the condition.  
 
Assessment is a more time-intensive process that may:  
• confirm whether the condition or disorder is present 
• assess its severity, impact and relevance, and the client’s perceptions, 
attitudes and beliefs about the condition or disorder  
• inform and develop integrated treatment planning around the disorder (in dual 
diagnosis, around both disorders). 
 
In practice, the distinction between screening and assessment is not so clearly 
defined. Many screening tools also provide useful assessment information. Once a 
clinician has integrated routine screening into their practice, the transition from 
screening to assessment will usually be imperceptible to the client. When sensitively 
deployed, screening processes can provide a further opportunity to build engagement 
with clients.  
 
Who should we screen? 
 
 
Like anyone else, clinicians may be vulnerable to assumptions about the type of 
person who is likely to have a particular disorder. This can lead a clinician to screen 
only those people who they consider fit the ‘profile’. All people with either a mental 
health or a substance use disorder are at substantially more risk of also developing 
the other disorder. If we only screen clients with a certain profile, we are likely to fail 
to detect co-occurring disorders in a number of our clients. Our guiding principle 
should be that all people receiving mental health or drug treatment services 
should be screened or assessed for a co-occurring disorder. 
 
 
When should we screen? 
 
 
It is not uncommon for mental health or AOD treatment to have been underway for 
some time before it becomes apparent that a co-occurring mental health or substance 
use disorder exists, and that it is impacting negatively on treatment. If the co-
occurring disorder had been recognised earlier, a treatment plan could have been 
developed that recognised the interplay of both disorders and their treatment needs. 
This potentially could mean a quicker return to healthy functioning for the client. Early 
recognition aids the development of the most useful possible treatment plan. Our 
guiding principle should be that all people receiving mental health or AOD treatment 
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 services should be screened or assessed for a co-occurring disorder at or near their 
first contact with the treating service. 
 
Engagement is paramount, however. While early screening is best practice, there will 
be situations in which screening for a co-occurring disorder may compromise the 
clinician’s best efforts to engage a client (for example, if a client states: ‘I came here 
because my wife wants me to address my depression and irritability. I am going to 
walk out the door if you ask me about my use of alcohol’). In those situations, 
screening should be deferred until rapport and the patient’s understanding of the 
rationale for screening permits screening.  
 
Young people presenting with either mental health or substance use symptoms or 
disorders are at particularly high risk of also developing the other disorder. Even if 
they are not positive for a co-occurring disorder on initial contact, they may well 
develop that disorder during engagement with your service. Hence, with younger 
people, there should be some level of screening for a co-occurring disorder at each 
contact. 
 
When shouldn’t we screen? 
 
 
Screening should be deferred when other treatment needs are more immediate. One 
would usually not screen for a co-occurring disorder when the client is intoxicated, 
distressed, in pain, in need of emergency treatment (Henry-Edwards, Humeniuk, Ali, 
Poznyak and Monteiro, 2003) or acutely psychotic.  
 
It is unethical to screen for any condition when there isn’t an accessible treatment 
pathway available to respond to a positive screen. This does not imply that the person 
conducting the screening or their service should necessarily be able to provide all of 
the required treatment themselves. Rather, where completely integrated treatment is 
not possible, the screening clinician should be confident in knowing where and how to 
link the client who screens positive to appropriate, evidence-based treatment of the 
screened-for disorder.  
 
What are the criteria for choosing a screening tool? 
 
 
There are a number of screening tools available to screen for either mental health or 
substance use disorders. The sections Screens for mental health symptoms and 
disorders and Screens for substance use disorders describe some of the 
screening tools currently used in Victorian mental health or AOD services. 
 
 
 
 
When selecting screening tools for your service useful criteria may be: 
• The tool’s : 
– reliability (ability to consistently detect the disorder) 
– validity (how accurate the screen is in detecting the disorder)  
– specificity (the degree to which the screen accurately identifies 
those people who do not have the disorder) 
– sensitivity (the degree to which the screen accurately detects people 
who do have the disorder).  
 
• How quickly and easily the tool can be used, scored and interpreted 
 
• If the tool screens for substance use disorders, is it sensitive to harmful use 
as well as dependence? 
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• Does the tool screen for the gamut of possible disorders (for example, AUDIT 
only screens for alcohol use disorders whereas ASSIST screens for all 
substance use disorders / many mental health screens do not indicate 
possible psychotic disorders). 
 
• Is the tool acceptable to, and understood by, other services that your agency 
relies on for consultation about, and treatment of, the target disorder? For 
example, if an AOD service regularly uses K10 as a mental health screen, it 
is desirable that local mental health services also understand K10 scoring 
and the tool’s strengths and limitations. 
 
• Can the  client complete the tool or  must it be administered by a clinician? 
 
• Is the tool in the public domain? Do you have to possess particular 
qualifications in order to use the tool? 
 
• Has the tool been well validated? Has the tool been validated with 
populations of people with mental health disorders, for example, with people 
with serious mental illness (SMI)? 
 
 
Our service already assesses all clients for co-occurring 
mental health/substance use disorders. Should we be 
screening them as well? 
 
 
Screening is best viewed as a quick yes/no guide as to whether a detailed 
assessment is warranted. If a service has the capacity, time and expertise to 
incorporate assessment of likely co-occurring disorders into their routine assessment 
process, then screening is superfluous. The reality is that many services and 
clinicians do not possess the necessary expertise, supports or time to routinely and 
adequately assess co-occurring disorders.  
 
A pivotal question with assessment-only protocols is how adequate is the assessment 
of the co-occurring disorder? A number of older mental health assessment proformas 
contain some limited substance use assessment criteria. In general these do not 
provide the depth of fine-grained information necessary to inform effective integrated 
treatment planning for clients presenting with co-occurring mental health and 
substance use disorders.  
 
Appendix 3: Sample substance use assessment form includes the minimum 
criteria necessary to include in a comprehensive substance use assessment. Such 
assessment proformas should be supported by training in conducting an accurate 
substance use assessment, policy, managerial ‘buy-in’ and file audit procedures.  
 
What are the barriers to routine integrated screening, 
assessment and treatment? 
 
 
There are a number of addressable factors that may mediate against mental health 
and AOD agencies developing routine screening, assessment and treatment of co-
occurring disorders. The following chart lists some of these potential barriers and 
possible strategies to address them.
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Barrier Possible strategies 
 
Lack of awareness of: 
• prevalence and harms 
associated with co-occurring 
disorders  
• likely interactions between 
disorders 
• treatment implications. 
 
 
Provide this information in multiple formats, for 
example: 
• training sessions  
• staff orientation procedures and manuals  
• client and carer education packages. 
 
Build agency capacity to record dual diagnosis 
data (screening results). 
 
 
Perception of added work, 
especially when clinicians may feel 
overwhelmed by multiple demands, 
stresses and paperwork, perhaps 
change-weary and change-wary! 
 
 
Promote view that the goal is more effective 
rather than added work – that recognising and 
addressing co-occurring disorders is likely to 
lead to more successful treatment of our target 
disorders.  
 
When introducing a new screening or 
assessment form, take the opportunity to 
review and simplify existing assessment forms 
and processes and remove some of the 
existing paperwork burden. 
 
 
Lack of familiarity with using 
screening tools and difficulty 
integrating their use into routine 
practice. 
 
 
Clinician concerns that client 
engagement may be compromised 
by formal screening for a disorder 
that the client hasn’t presented for 
help with. 
 
 
• Provide information about the rationale for 
screening and assessment. 
 
• Provide training, modelling and clinical 
supervision around seamlessly integrating 
screening into routine practice. 
 
• Include careful explanation to clients of the 
rationale for and confidentiality of 
screening. 
 
Clinicians may lack skills, 
knowledge and confidence in their 
ability to provide appropriate 
treatment for a co-occurring disorder 
and so be reluctant to ask questions 
that would lead to the identification 
of that disorder. 
 
 
• Provide education, training and realistic 
evidence for optimism about 
effectiveness of treatment.  
 
• Address clinician ‘self-efficacy’ about 
providing effective treatment. 
 
Lack of clarity about scope of 
practice. For example, some AOD 
workers may have anxiety about 
whether it is within their scope of 
practice to conduct a detailed risk 
assessment? 
 
 
• Clarify explicit scope of practice 
guidelines and treatment manuals. 
 
• Promote tools which contain an 
integrated risk assessment, e.g. 
PsyCheck 
 
 
Implication of current ‘wrong 
practice’. 
 
Reframe the development of integrated 
screening, assessment and treatment as an 
evolutionary step towards more effective 
treatment approaches. 
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Changes to practice, language, 
beliefs, values, exclusion criteria. 
 
Use policy to reinforce that addressing co-
occurring disorders is core business for both 
mental health and AOD treatment agencies 
 
 
Stigma of client group – two 
relapsing, highly stigmatised 
disorders in the one individual. 
 
 
The clinician’s own cognitive 
dissonance: for example, to address 
my client’s substance use or mental 
health issue, it is necessary (at 
some level) to examine my own 
substance use or mental health 
issues. 
 
History of own substance-related or 
mental health-related trauma. 
 
 
Encourage treatment providers to identify their 
own attitudes and feelings evoked by dealing 
with the disorder. 
 
Provide integrated treatment-oriented clinical 
supervision. 
 
Lack of knowledge of the ‘opposite’ 
treatment system, its strengths, 
differences and constraints on 
service. 
 
 
Provide opportunities for understanding and 
maximise formal and informal contacts 
through: 
• Rotations and placements with the 
opposite service 
• Joint training 
• Routine provision of service from the 
opposite agency.  
• Worker-developed protocols.  
• Co-location.  
• Scheduled, regular interagency 
managerial and clinician meetings 
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What are the issues in screening with younger people? 
 
 
Compared to adults, younger people will tend to: 
• be more likely to see substance use as a solution rather than a problem 
• be more likely to be experimenting with a range of substances 
• be less likely to meet the criteria for substance dependence (but will frequently 
meet the criteria for harmful use – see Appendix 5). 
 
Key issues around screening for co-occurring substance use or mental health 
disorders in young people include: 
 
1. Confidentiality and disclosure – in what circumstances should the results 
of a positive screen and assessment be shared with the young person’s 
carers? In general, your agency’s policies around consent and disclosure 
with ‘target disorders’ will also guide you around consent and disclosure 
about co-occurring disorders. 
 
2. The age at which screening should be instituted – around one in four 
young people aged 12–14 years drink some alcohol and nearly a third of 
Australian children report binge drinking by age 15. The emerging 
consensus, among Victorian youth mental health services that have 
implemented substance use screening, is that around 12 years is an 
appropriate age to commence screening for co-occurring substance use 
issues.  
 
Mental health disorders are highly prevalent among young people. Youth 
AOD service clinicians should be alert to the possibility of co-occurring 
mental health disorders, whatever the age of their clients. 
 
3. Screening approaches – which tools are appropriate for use and when?  
Tools being used to screen for mental health disorders in young people 
presenting to Victorian youth AOD services include the K10 and the Youth 
Mental Health Screener, currently under development and evaluation by 
ORYGEN Research Centre and their partners: more details at 
http://www.orygen.org.au/contentPage.asp?pageCode=SUBUSE 
 
Tools being used to screen for substance use disorders in young people 
presenting to Victorian mental health services include: 
• ASSIST 
• AUDIT (alcohol only) 
• CRAFFT 
 
The CAGE is not recommended for use among adolescents. 
 
 Page 12
 After screening – the next steps 
Once a co-occurring disorder has been detected (through screening) and an 
assessment completed, the challenge facing mental health and AOD services 
and clinicians is to determine how they can best achieve the most effective 
treatment of both disorders. 
Developing the most effective possible response 
to both disorders 
An understanding of three key concepts can assist in the development of the 
most effective possible treatment for people with co-occurring disorders.  
1. Locus of treatment responsibility 
2. Integrated treatment 
3. A ‘no wrong door’ service system 
1. Locus of treatment responsibility 
The predominant mix of co-occurring disorders tends to be different in AOD 
treatment and mental heath settings. Most Clinical Mental Health Services and 
Psychiatric Disability Rehabilitation and Support Services (PDRSS) have a 
necessary focus on people with the highest acuity of need and/or more complex 
treatment needs as a result of having a Serious Mental Illness. People with these 
disorders are at high risk of either harmful use or dependence involving a wide 
range of substances. A different predominant cohort of people with co-occurring 
disorders is found in primary mental health settings, which tend to focus on 
people with high-prevalence, low-impact disorders or mental health disorders 
(such as anxiety and depression). People receiving treatment for anxiety and 
depression have a high prevalence of co-occurring alcohol harmful use or 
dependence. 
 
In contrast, the primary focus of AOD treatment services tends to be on people 
with severe substance use disorders. People with severe substance use 
disorders often also experience anxiety and depression symptoms or disorders 
and/or personality disorder.  
 
There is great variability in the treatment needs of the various cohorts of people 
with co-occurring disorders. Guidance about which sector of the treatment system 
should have treatment responsibility for the various cohorts can be found in the 
2007 Victorian DHS Policy, Dual Diagnosis: Key directions and priorities for 
service development. This policy proposes a three-level schema for responding to 
dual diagnosis (see Figure 1). 
 
This schema assigns treatment responsibility for the various cohorts of people 
with dual diagnosis to either specialist mental health (Tier 3: People with Serious 
Mental Illness with or without a substance use disorder), specialist drug treatment 
(Tier 2: People with severe substance use disorders with or without symptoms of 
mental illness) or primary care (Tier 1: People experiencing lower severity mental 
health problems and lower severity drug and alcohol problems). 
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Figure 1: Three-level schema for responding to dual diagnosis 
From: Dual Diagnosis: Key directions and priorities for service 
development. 2007. Victorian DHS 
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 2. Integrated treatment  
 
The development of the most effective possible treatment responses to the needs 
of people with co-occurring disorders rests on providing or facilitating integrated 
treatment for both presenting disorders. Integrated treatment can be defined as 
one clinician or agency providing treatment of both a client’s substance use and 
mental health disorders. Integrated treatment also occurs when clinicians from 
separate agencies collaborate to ‘develop a single treatment plan addressing 
both sets of conditions and the continuing formal interaction and cooperation of 
these providers in the ongoing reassessment and treatment of the client’ (CSAT, 
2005) – that is, an Integrated Treatment Plan. 
 
 
 
 Integrated treatment may be provided by a clinician who 
treats both the client’s substance use and mental health 
problems. 
 
Integrated treatment can also occur when clinicians from 
separate agencies agree on an individual treatment plan 
addressing both disorders and then provide treatment. 
 
This integration needs to continue after any acute 
intervention by way of formal interaction and co-operation 
between agencies in reassessing and treating the client.  
Table 2: Integrated treatment defined 
Dual Diagnosis: Key directions and priorities for service development 
(2007 Victorian DHS) 
 
 
The strongest indications, if not evidence, that we have from research suggest 
that integrated treatment of co-occurring disorders tends to be more effective than 
non-integrated treatment for many people with co-occurring disorders. On face 
value alone, it would appear to make  sense not to require a client to have the 
skills and motivation to engage with and negotiate two different service systems; 
that is, to have the ingenuity and flexibility to compartmentalise their disorders 
sufficiently to work on them with separate clinicians in separate systems. 
 
It is a reality of most service systems that the various clinicians, agencies and 
sectors have differing capacities to provide ‘in-house’, ‘one-stop-shop’, integrated 
treatment for the variety of mental health and substance use disorders. In fact, at 
this point in our evolution, few mental health or AOD agencies have the capacity 
to provide in-house, mono-agency, integrated treatment for the whole gamut of 
possible mental health and substance use disorders. Some services do have the 
capacity to provide such treatment for some of the cohorts of people with co-
occurring disorders. All services should be actively developing their capacity to 
routinely develop integrated treatment plans with services from the ‘other’ sector. 
All services, if they do not already, should be rapidly developing their capacity to 
routinely develop integrated treatment plans with services from the ‘other’ sector.  
 
Generally, mental health services do not have, and are unlikely to have, the 
capacity to provide routine opiate pharmacotherapies or to provide routine home-
based, substance detoxification services; though they may at times need to 
dispense pharmacotherapies and routinely manage withdrawal in people 
undergoing psychiatric admission. Similarly AOD services cannot be expected to 
oversee the safety needs of a person who is acutely suicidal or to provide mental 
health treatment for a person with acute Serious Mental Illness, though they may 
at times provide drug treatment services to people with psychosis or continue 
engagement with a person who is suicidal while mental health services respond 
to the person’s acute mental health needs.  
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 However, in all of these cases: 
• Screening by each sector increases the likelihood that co-occurring 
disorders will be recognised. 
• Assessment of co-occurring disorders informs treatment planning and 
makes it more likely that treatment planning will be effective. 
• Collaboration on an Integrated Treatment Plan increases the likelihood 
that treatment of all disorders will be effective. 
 
The 2007 Victorian DHS Policy, Dual Diagnosis: Key directions and priorities for 
service development, provides guidance about optimal integrated and 
collaborative treatment responses to people with co-occurring disorders by AOD 
and mental health clinicians and services.  
 
  Tier 3: Dual diagnosis capable staff in specialist mental health 
services should: People with severe mental • provide integrated treatment to the majority of clients with 
severe mental disorders and substance use  health problems and disorders • collaborate with drug and alcohol services in joint service 
provision for those whose needs are best met through 
collaboration across rather than within the service 
(Serious Mental 
Illness) with or 
without a • provide secondary consultation to staff in other sectors 
regarding the treatment of mental health disorders 
substance use 
disorder   
 
Dual diagnosis capable staff in drug and alcohol services 
should: Tier 2: 
• provide integrated treatment to clients who experience 
severe substance use problems and lower severity 
mental health problems;  
People with 
severe substance 
use disorders 
with or without • collaborate with mental health services in service 
provision; and symptoms of 
mental illness • provide secondary consultation regarding the treatment 
of problematic drug and alcohol use to other sectors. 
 
Table 3: Scope of practice for Victorian AOD and Mental Health clinicians 
and services in responding to the treatment needs of persons with dual 
diagnosis 
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 Case examples: Integrated treatment 
 
1 clinician 
/ agency 
treating 
both 
problems: 
 
 
Client: Adam - 42 year old, separated, employed male referred from 
General Practitioner for help with Alcohol Dependence 
 
Mental Health Screening: (with PsyCheck)  
• no past treatment for any mental health disorder 
• no suicidal ideation 
• some mild symptoms of depression & anxiety 
 
Treatment provided by AOD worker: 
• Completed home based alcohol withdrawal 
• Relaxation training 
• Cognitive Behavioral Therapy addressing symptoms of depression  
• Relapse Prevention plan developed for both disorders 
 
 
Integrated 
Treatment 
Examples 
 
1. 
 
AOD 
agency 
 
 
Eve
Multi 
agency 
integrated 
treatment: 
 
Client:  - 22 year old, single unemployed female self-referred for 
assistance with Methamphetamine Abuse 
 
Mental Health Screening: (with PsyCheck) indicated  
• Sporadic episodes of  treatment for anxiety since 17 years old (by 
local GP & private psychologist) 
• moderate suicide risk 
• marked symptoms of depression & anxiety 
 
Further assessment indicated: 
• Eve presents as irritable and suspicious with concerns that others 
can read her thoughts. 
 
Treatment: 
The AOD worker initiated a telephone consult with local Clinical Mental 
Health Service triage with the outcome that Eve agreed to an 
immediate joint appointment with the mental health worker and AOD 
worker. At that appointment a safety plan was negotiated involving 
support from Eve’s parents and daily contact with mental health worker. 
At a subsequent joint appointment a Individual Service Plan, signed off 
by both services and the client, was developed which involved                  
• the mental health worker/service monitoring and managing Eve’s 
suicidality 
• AOD worker providing counselling around Eve’s amphetamine use 
(Motivational Interviewing / Goal Setting / Relapse Prevention) 
• Both workers communicating with the other after each contact with 
Eve and her family (consent forms signed by Eve) 
• Further joint session when either service was planning discharge 
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1 clinician / 
agency 
treating 
both 
problems: 
 
Client: Darby - 22 year old male with a 5 year history of schizophrenia. 
Receiving treatment from GP only for past year and taking psychotropic 
medication as prescribed.  Now presents with recurrence of auditory 
hallucinations and paranoid ideation. Nil suicidal ideation or history 
 
AOD Screening: (with ASSIST)  
• Showed, in the past 3 months, daily use of tobacco, weekly use of 
alcohol and weekly use of amphetamines 
• Nil other recent substance use 
 
Treatment provided by Mental Health clinician: 
• Medication review with psychiatrist 
• Detailed Substance Use Assessment completed including stage of 
change in regards to both treatment of psychosis (in Action) and 
use of amphetamines (Contemplative / ambivalent). Nil substantial 
issues with withdrawal 
• ICD 10 substance use diagnoses recorded alongside ICD 10 
psychiatric diagnoses 
• Individual Service Plan developed that addressed both psychotic 
symptomatology and amphetamine use  
• Brief Intervention and psycho-education provided around 
association between amphetamines and psychosis 
• In the course of treating Darby’s psychosis the mental health 
clinician used Motivational Interviewing strategies to address his 
use of amphetamines 
• By discharge an integrated relapse prevention plan had been 
developed which addressed both psychotic symptomatology and 
amphetamine use. 
 
Integrated 
Treatment 
Examples 
 
2. 
 
Multi 
agency 
integrated 
treatment: 
 
Client: Joan - 69 year old widowed woman referred to Aged Psychiatry Clinical by her GP with a 4 year history of social withdrawal, depression and 
Mental possible dementia 
 Health 
AOD Screening: (with AUDIT)  
• Score of 27 indicated likely Alcohol Dependence 
 
Further assessment indicated: 
• Memory clinic and diagnostic investigations did not reveal 
significant cognitive impairment 
• Detailed Substance Use History revealed some abuse of 
prescribed medications and a 5-year history of alcohol abuse (since 
the death of her husband). Nil other substance use. 
 
Treatment provided: 
Mental Health worker sought consultation with local AOD service. An 
outcome was that the AOD and mental health worker conducted a joint 
home visit. An Individual Service Plan, signed off by both services and 
the client, was developed which involved: 
• Local AOD service facilitating and supporting Joan through a 
hospital based alcohol withdrawal  
• Mental Health service reviewing and monitoring Joan’s medication, 
increasing social supports and discharge planning 
• Each worker/ service regularly communicating with the other (and 
referring GP) 
 
 
 Page 18
  
 
 
 
 
1 clinician 
/ agency 
treating 
both 
problems: 
 
 
Client: Jill - 39 year old single woman with long standing 
engagement with the PDRS service and a 15 year diagnosis of 
Borderline Personality Disorder  
 
AOD Screening: (with ASSIST) 
• Revealed, in the past 3 months, weekly use of alcohol,  
sedatives or sleeping pills and monthly use of opioids  
 
Treatment provided by PDRSS worker: 
• Completed a detailed substance use history 
• In counseling Jill examined the links between substance 
use and periods of maximum distress.  
• With her worker Jill refined her Individual Treatment Plan to 
put in place further, substance use related,  early warning 
signs of self-destructive behavior as well as suggestions of 
how she would prefer workers to respond when these early 
warning signs occur 
 
 
Integrated 
Treatment 
Examples 
 
3. 
 
Psychiatric 
Disability 
Support 
Service 
  
 
 
 
 
 
 
Multi 
agency  
integrated 
treatment: 
 
Client: Jack - 42 year old, divorced, unemployed man with 15 
year history of schizoaffective disorder. Lives in independent 
accommodation with near daily support from the PDRS service  
 
AOD Screening: (with ASSIST) 
• Revealed daily use of tobacco, cannabis and alcohol over 
the past 3 months 
 
Further assessment:  
• PDRSS worker completed a detailed substance use 
assessment which recognised that Jack was keen to 
moderate his use of alcohol but had found this difficult due 
to withdrawal symptoms. Precontemplative about use of 
tobacco and cannabis.  
 
Treatment provided : 
PDRSS worker sought consultation with local AOD service and 
then accompanied Jack to an initial appointment with the local 
AOD service. An Individual Treatment  Plan, signed off by both 
services and the client, was developed which involved: 
• the AOD and PDRS worker jointly supporting Jack through 
a home-based withdrawal 
• Both AOD & PDRS  workers opportunistically  deploying 
Motivational Interviewing strategies addressing Jack’s 
cannabis use  
• Frequent communication between the workers / services 
and a date set to again review Jack’s progress and 
Individual Treatment  Plan 
• AOD agency providing the PDRS staff with education on 
Motivational Interviewing and withdrawal.  
• PDRS service providing the AOD staff with education on 
Psychiatric Disability and strengths-based interventions 
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 3. ‘No wrong door’ service system 
 
The 2007 Victorian DHS Policy, Dual Diagnosis: Key directions and priorities for 
service development prioritises the further development of a No Wrong Door 
service system. This goal has been developed around the recognition that people 
with both a mental health and a substance use disorder are at high risk of ‘falling 
through the gaps’ and missing out on receiving an appropriate service from 
anywhere in the service system. 
 
In a No Wrong Door service system, in those cases where a person is assessed 
and it is deemed that they do not meet the criteria for a service from the agency 
that they have presented to, but that service from another agency is indicated, 
then that person should still be warmly welcomed and actively and meaningfully 
assisted in gaining a service from the most appropriate treatment agency (Croton, 
2004). 
 
The chief implication for workers in either system is that, when they encounter a 
person who does not meet the criteria for service from their own agency, their 
next step should be to work with that person to establish where they are likely to 
get the most useful service and to actively assist the person to obtain that service. 
 
 
No wrong door case example 
 
 
Paul 
John, a mental health worker, was called out at 2 am to assess Paul. Paul had 
been found alcohol intoxicated, walking on a bridge over a railway line, with 
contusions from an earlier altercation. Due to the location in which he had been 
found, emergency department staff had concerns that Paul may have been 
suicidal.  
 
On assessment Paul is a 36-year-old, separated, unemployed male with two 
children. He is cooperative, pleasant, alcohol affected but lucid and convincingly 
denies past or present suicidal ideation. He has a breathalyser reading of 1.4. 
John quickly established that Paul meets the criteria for alcohol dependence. 
 
John engaged well with Paul and was successful in getting Paul to agree to come 
and see him early the following afternoon. In that session, they discuss the 
previous night’s events. John assists Paul to develop his decisional balance 
around alcohol use and establishes that Paul is interested in making some 
changes to his alcohol consumption.  
 
Paul agrees to John’s proposal of a further appointment (still in the mental health 
service office). He also agrees that John will ask a colleague from the local AOD 
service to their next meeting, who would be better placed to assist Paul with 
working on his alcohol use goals. 
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 Are we going to have to treat more people? 
We are a mental health We are an AOD service. 
service. Does all this mean Does all this mean that we 
that we are going to have to are going to have to treat 
treat people with substance people with mental health 
use disorders AS WELL as disorders AS WELL as 
people with mental health people with substance use 
disorders? disorders? 
 
It is not intended that either mental health or AOD services should vary their 
primary criteria for entry to their service system. Rather, that where people who 
do meet criteria for their services also have a co-occurring disorder, that co-
occurring disorder will be routinely detected and assessed, and a Integrated 
Treatment Plan developed that responds to both mental health and substance 
use treatment needs. The goal is to have mental health workers highly attuned to 
co-occurring substance use issues and substance use treatment workers highly 
attuned to co-occurring mental health issues. 
 
Mental health services will not be treating people who have a substance use 
disorder alone. AOD services will not be treating people who have a mental 
health disorder alone. 
 
In pursuit of a No Wrong Door service system, both AOD and mental health 
services may, in some circumstances, briefly invite someone without the 
necessary substance use disorder criteria (in the case of AOD) or mental health 
criteria (in the case of mental health services) into their systems with the sole aim 
of linking that person as efficiently as possible to the service system that best 
meets their particular treatment needs. 
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Screens for mental health symptoms and 
disorders 
 
What are they and where can I get them? 
 Page 22
  
K10 
 
The K10 is a screening tool that can also be used as a rating scale/outcome measure.  
 
The K10 was primarily designed to detect high-prevalence mental health disorders, but there is also an 
argument that high K10 scores may be an indicator of possible Serious Mental Illness. 
 
The K10 is now in widespread Australian and international use - for example, as a Victorian Service 
Coordination Tool, a NSW mental health routine outcome measure, and by organisations such as the Armed 
forces, Beyond Blue and by doctors in General Practice. The K10 was used in the 1997 Australian National 
Survey of Mental Health and Wellbeing. 
 
Scores range from 10 to 50: 
 
Level of anxiety or K10 score SCT K10 version recommended responses depressive disorder 
Low or no risk ------- 10 to 15 
Medium risk Refer for primary care mental health assessment 16 to 29 
High risk Refer for specialist mental health assessment 30 to 50 
 
Screens for: Distress 
 
Time to complete and score: 10 items – 2 minutes 
 
Public domain? Yes 
 
Can client complete it? Yes. The K10 can also be interviewer-administered to people with poor reading 
ability. 
 
Where can I get it? 
Service Coordination Tool Templates (SCTT) version: 
http://www.health.vic.gov.au/pcps/downloads/coordination/tool_profile_psychosocial_may02.pdf
 
 
Online electronic version and scoring: http://www.beyondblue.org.au/index.aspx?link_id=1.237
 
More information: 
http://www.crufad.com/K10/k10info.htm
 
Strengths: 
• Brief 
• Very easy to use 
• Well known 
• Client can complete 
• SCTT version contains graduated guidelines about need for mental health assessment 
• Can be used as a outcome measure. 
 
Possible limitations: 
• Non-specific measure of psychological distress only; still requires clinician judgment as to whether a 
person needs mental health treatment. 
• Most specialist mental health services are orientated primarily around Serious Mental Illness – the K10 is less 
sensitive to these disorders. 
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PsyCheck 
 
‘The PsyCheck Screening Tool is a mental health screening instrument designed for use by non-mental health 
specialists. It is not designed to be a diagnostic assessment and will not yield information about specific 
disorders’ (Lee et al., 2007).  
 
Now that PsyCheck is in the public domain, it may well become the ‘gold standard’ for Australian AOD 
services. 
 
PsyCheck is comprised of: 
• Self Reporting Questionnaire (WHO mental health screen) 
• Suicide risk assessment 
• Brief mental health history 
• Mental health probes. 
 
In sites where the PsyCheck project was rolled out as a demonstration project, workers were skilled up in 
deploying a linked cognitive behavioural intervention in response to positive PsyCheck screens. 
 
Screens for:  
• Likely presence of mental health symptoms that may be addressed within specialist AOD treatment 
services.  
• Primarily screens for anxiety and depression but also provides some indication of suicide risk and 
history of psychotic illness. 
 
Public domain? 
Yes 
 
More information: 
Lee, N., Jenner, L., Kay-Lambkin, F., Hall, K., Dann, F., Roeg, S., Hunt, S., Dingle, G., Baker, A., Hides, L. & 
Ritter, A. (2007), PsyCheck: Responding to mental health issues within alcohol and drug treatment, Canberra, 
ACT: Commonwealth of Australia. 
 
Can client complete it? 
No 
 
Strengths: 
• Attached optional risk assessment 
• Likely to be in wide-spread use in Australian AOD services once in the public domain 
• Linked cognitive behavioural intervention 
• Australian developed. 
 
Possible limitations: 
• Not yet in widespread use 
 
 
 
 Page 24
  
Modified Mini Screen (MMS) 
 
Screens for:  
The MMS is designed to identify people in need of an assessment in the domains of mood disorders, anxiety 
disorders and psychotic disorders. It is not diagnostic per se, but is intended as an indicator of when more 
thorough mental health assessment is required. 
 
Time to complete and score: 10 to 15 minutes 
 
Public domain? 
Yes 
 
Can client complete it? 
Yes (not scoring) 
 
Where can I get it? 
OASAS – MMS Tool: http://www.oasas.state.ny.us/hps/research/documents/MMSTool.pdf  
 
OASAS – Screening for co-occurring disorders using the Modified Mini Screen (MMS) – User’s Guide: 
http://www.oasas.state.ny.us/hps/research/documents/MINIScreenUsersGuide.pdf  
 
Connecticut Department of Mental Health and Addiction Services: 
http://www.dmhas.state.ct.us/cosig.htm#screening  
(English and Spanish versions paired with CAGE-AID AOD screen.) 
 
 
 
Mental Health Screening Form 
 
Screens for:  
17-item screen that examines lifetime history. Questions 1–4 are about client’s history of psychiatric treatment. 
Each of questions 5—17 is associated with a particular mental health diagnosis. Positive responses to these 
items suggest the need for more intensive assessment or consultation with a mental health professional. 
 
Time to complete and score:About 10 minutes 
 
Public domain? 
Yes 
 
Can client complete it? 
Yes (not scoring)  
 
Where can I get it? 
Versions available at: 
http://www.asapnys.org/Resources/mhscreen.pdf
 
http://pathwayscourses.samhsa.gov/bully/pdfs_bully/bully_supps_pg40.pdf
 
Connecticut Department of Mental Health and Addiction Services: 
http://www.dmhas.state.ct.us/cosig.htm#screening  
(English and Spanish versions paired with Simple Screening Instrument for Alcohol and Other Drugs).  
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Screens for substance use disorders 
What are they and where can I get them? 
 Page 27
  
Sensitive Questioning 
 
Clinician concerns about introducing screening tools into their practice are common (see FAQs section, What 
are the barriers to routine integrated screening, assessment and treatment?).Clinicians may feel that the 
use of a validated screen will impede their engagement with the client, disrupt the client’s narrative or be 
unwelcome by the client when s/he has presented due to concerns other than substance use.  
 
Clinicians may already routinely incorporate questions about substance use into their mental state 
assessments. Whether such questions will be effective in detecting co-occurring substance use disorders will 
depend on a number of factors, including: 
• clinician’s attitude to and beliefs about people with (highly-stigmatised) substance use disorders 
• clinician’s orientation to detecting and responding to less visible substance abuse as well as substance 
dependence 
• clinician’s recognition of the prevalence of co-occurring substance use disorders in people with mental 
health disorders  
• clinician’s understanding of likely impacts on treatment effectiveness of a co-occurring substance use 
disorder 
• clinician’s confidence and competence in providing or obtaining treatment for any co-occurring 
substance use disorder detected 
• how the questions are worded. 
 
 
Useful strategies: 
For initial screening purposes, all questions should be open-ended and non-judgemental. ‘Do you have a 
problem with your use of alcohol or other drugs?’ is both close-ended and judgemental. A better strategy would 
be to normalise possible substance use (e.g. ‘Many people experiencing all this would have a drink to help 
them cope’) before asking an open-ended question (Could you tell me about your use of alcohol?’). 
 
In general, clinicians should ask about all drugs, naming them individually, and provide clear timelines for their 
enquiry. Question 2 of the ASSIST screen provides an ideal template for such questioning (i.e. Could you tell 
me about your use, in the past 3 months of Tobacco / Alcohol / Cannabis / Cocaine / Amphetamine-type 
stimulants / Inhalants / Sedatives or Sleeping Pills / Hallucinogens / Opioids).   
 
Incorporate questions about substance use into routine lifestyle questioning. An explanation to the client around 
the common interacting effects of substance use with mental health issues may increase the likelihood of the 
client providing accurate information. 
 
 
Principle: If the client is reluctant to disclose information about their substance use, this is important feedback 
to the assessing clinician about the client’s perception of the clinician’s attitude and language (i.e. the client’s 
may perceive that the clinician is negatively judging their substance use) and an indicator that the clinician 
should be at pains to convey a neutral, inquisitive attitude to the client’s substance use 
 
Sensitive questioning, as with other screening methods, should be supported by the clinician’s knowledge of 
physical and behavioural presentations that may indicate possible substance use disorders. Clinicians should 
be alert to the reports of significant others and, where available, note relevant pathology/laboratory reports. 
 
Jumping into providing advice or commenting on a client’s substance use in the screening/assessing phase of 
client engagement is likely to impede their willingness to provide further information. 
 
 
Some possible questions: 
Has a relative, friend, doctor or other health worker been concerned about your drinking or other drug use, or 
suggested that you may want to cut down? 
 
Have you ever said “No, I don’t have an alcohol or drug problem” when, around the same time, you 
questioned yourself and felt,  “Maybe I do have a problem”? 
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Strengths: 
• May dovetail more smoothly with strictly narrative assessment approaches. 
  
 
Possible limitations: 
• Where clinicians lack comfort and confidence in detecting and responding to co-occurring substance 
use issues, ineffective questioning approaches can become a strategy to avoid dealing with client’s co-
occurring substance use disorders. 
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AUDIT 
Screens for: 
• Alcohol use disorders (past-year time frame).  
• ‘Gold standard’ for providing an indication of both hazardous/harmful alcohol use as well as alcohol 
dependence.  
 
Created by: 
World Health Organisation. 
 
Time to complete and score: 
• 10 items, each with a 5-point likert scale.  
• 2 minutes to complete & 1 minute to score. 
• May well prompt a brief intervention. 
 
Scoring: 
• 0-7:   Low risk 
• 8-15: Harmful or hazardous drinking 
• >15:  High risk of harm & possible alcohol dependence 
• >20:  Definite harm and likely to be dependant 
Sub-scores: 
• High scores on items 1-3 suggests hazardous use 
• High scores on items 4–6 suggests dependence 
• High scores on items 7–10 suggests harmful use.  
 
Treatment responses: 
• Scores between 8 and 15 are most appropriate for simple advice focused on the reduction of hazardous 
drinking. 
• Scores between 16 and 19 suggest brief counseling and continued monitoring. 
• Scores of 20 or above clearly warrant further diagnostic evaluation for alcohol dependence 
(2001, Babor, Higgins-Biddle, Saunders,  Monteiro) 
 
Public domain? Yes 
 
Can client complete it? Yes 
 
Where can I get it? 
This tool is available from many websites.  
 
The WHO’s Alcohol Use Disorders Identification Test Guidelines for Use in Primary Care is downloadable from 
http://whqlibdoc.who.int/hq/2001/WHO_MSD_MSB_01.6a.pdf  
 
Australian Government Department of Veterans’ Affairs has a very well-constructed example (with scoring 
guidelines) available at http://www.therightmix.gov.au/pdfs/HealthProviderAUDIT.pdf  
 
Strengths: 
• Screens for the whole range of possible substance use disorders (particularly suitable for specialist mental 
health services) 
• Indicates both likely abuse and dependence 
• Also generates detailed assessment information 
• Has a linked brief intervention that is likely to be effective with people with problematic or risky substance 
use (rather than dependence). 
 
Possible limitations: 
Requires some concentrated effort to incorporate seamlessly into routine practice. 
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ASSIST 
 
Screens for:  
• substances people ever used (lifetime use) 
• substances used in past three months 
• problems related to substance use 
• risk of harm (current or future) 
• dependence 
• intravenous drug use. 
 
The ASSIST can … 
• warn people of their risk of developing problems related to their substance use  
• provide an opportunity to start a discussion about substance use  
• identify substance use as a contributing factor to the presenting illness  
• be linked to a brief intervention to help high-risk substance users to cut down or stop their drug use and 
avoid the harmful consequences of their substance use. 
 
The ASSIST can distinguish between three main groups:  
• low-risk substance users or abstainers 
• those whose patterns of use put them at risk of problems/who have already developed problems/who 
are at risk of developing dependence 
• those who are dependent on a substance. 
 
Time to complete and score: 
An experienced clinician can conduct an ASSIST screen and deliver the integrated brief intervention in 10 to 20 
minutes. 
 
Public domain? Yes 
 
Can client complete it? No. This tool is clinician administered. 
 
Where can I get it? 
http://www.who.int/substance_abuse/activities/assist/en/index.htmlThe ASSIST questionnaire is available from: 
(Versions in English, German, Hindi, Portuguese) 
Manual: ASSIST: Guidelines for Use in Primary Care [PDF 244kb]
Manual: Brief Intervention for Substance Use: A Manual for Use in Primary Care [PDF 164kb]  
Manual: Self-Help Strategies for Cutting Down or Stopping Substance Use: A Guide [PDF 424kb]
Project fact sheets and validation report. 
 
Strengths: 
• Indicates both likely abuse and dependence 
• Generates some assessment information 
• Has a linked brief intervention that is likely to be effective with people with problematic or risky 
substance use (rather than dependence). 
 
Possible limitations: 
• Requires some concentrated effort to incorporate into routine practice. 
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CAGE / CAGEAID 
 
Screens for:  
CAGE is a 4-item screen useful for detecting alcohol dependence.  
 
CAGEAID (Adapted to Include Drugs) has been developed to screen for severe drug use disorders. 
 
Time to complete and score: 1 minute 
 
Public domain? Yes 
 
Can client complete it? No. This tool is clinician administered. 
 
Where can I get it? 
Right here: 
 
CAGE: 
• Have you ever felt you should cut down on your drinking?  
• Have people annoyed you by criticising your drinking?  
• Have you felt bad or guilty about your drinking?  
• Have you ever had a drink first thing in the morning to steady your nerves or get rid of a hangover (eye-
opener)?  
 
CAGEAID: 
• Have you felt you ought to cut down on your drinking or drug use?  
• Have people annoyed you by criticising your drinking or drug use?  
• Have you felt bad or guilty about your drinking or drug use?  
• Have you ever had a drink or used drugs first thing in the morning to steady your nerves, get rid of a 
hangover or to get the day started? 
 
 
Scoring: Two positive answers indicate need for more detailed assessment. 
 
Strengths: 
• No training necessary to be able to administer 
• Easily memorised. 
 
Possible limitations: 
• Only indicates dependence. Not sensitive to abuse 
• Not suitable for use with younger people. 
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 Appendix 1: Sample screening protocol for a mental 
health service 
 
 
Protocol 
Screening for co-occurring Substance Use Disorders 
 
Agency: ……………………………………………………. 
 
This service: 
- Recognises that people receiving treatment for a mental health disorder are at substantially increased risk of 
also experiencing a substance use disorder. 
 
- Considers that mental health and substance use disorders most often, where they co-occur in an individual, 
will influence each other and are likely to impact on the individual in regard to development of the disorders, 
their severity, their response to treatment and their relapse circumstances. 
 
- Recognises that recognising, assessing and developing Integrated Treatment Plans that address co-occurring 
substance use disorders is core business for this service. 
 
- Considers that improving our detection of co-occurring substance use problems is likely to improve the 
effectiveness of our treatment of mental health disorders. 
  
-Prioritises timing the screening for and assessment of co-occurring substance use disorders as close as 
practicable to a client’s initial contact with the service.  
 
- Supports the following range of approaches to the detection and assessment of co-occurring substance use 
problems. 
 
Approach 1: 
- When providing a mental health assessment, clinicians from this service will routinely incorporate detailed 
questioning about substance use in the past three months. They will ask specifically about use of each of:  
 
Used in past three Substances months? 
Tobacco  
Alcohol  
Cannabis  
Cocaine  
Amphetamine-type stimulants  
Sedatives  
Hallucinogens  
Inhalants  
Opioids  
Other drugs  
 
- Positive response to any of the latter nine items will trigger the delivery of a full substance use assessment.  
 
- Identification of any substance use disorder in assessment triggers integrated recording of substance use 
disorder diagnosis/es alongside mental health diagnosis/es and  
integrated treatment planning around both disorders. 
 
 
Approach 2: 
- Routine screening using WHO ASSIST screen. 
 
- Utilise ASSIST guide to type of intervention being determined by ASSIST score (below). Tempered by 
clinician judgement/immediate treatment priorities. 
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- If the person qualifies for either a brief intervention or more intensive treatment, then this should trigger a 
full substance use assessment (see Appendix 3). 
 
- If assessment confirms diagnosis of a substance use disorder, then this will usually trigger 
i) integrated recording of substance use disorder diagnosis/es alongside mental health diagnosis/es, and  
ii) integrated treatment planning around both disorders. 
 
Approach 3: 
- Routine detailed substance use assessment of all people receiving a mental health assessment. 
 
- Identification of any substance use disorder in assessment triggers:  
i) integrated recording of substance use disorder diagnosis/es alongside mental health diagnosis/es, and  
ii) integrated treatment planning around both disorders. 
 
Situations where routine screening should be deferred: 
Routine screening will be deferred when the client is intoxicated, distressed, in pain, in need of emergency 
treatment or acutely psychotic.  
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 Appendix 2: Sample screening protocol for an AOD 
treatment service 
 
 
Protocol 
Screening for co-occurring Mental Health Disorders 
 
Agency: ……………………………………………………. 
 
This service: 
- Recognises that people receiving treatment for a substance use disorder are at increased risk of also 
experiencing a mental health disorder. 
 
- Considers that substance use and mental health disorders most often, where they co-occur in an individual, 
will influence each other and impact on the individual in regard to the development of the disorders, their 
severity, their response to treatment and their relapse circumstances. 
 
- Recognises that recognising, assessing and developing Integrated Treatment Plans that address co-occurring 
mental health symptoms and disorders is core business for this service. 
 
- Considers that improving our detection of co-occurring mental health problems is likely to improve the 
effectiveness of our treatment of substance use disorders. 
  
- Prioritises timing screening co-occurring mental health symptoms and disorders as close as practicable to a 
client’s initial contact with the service.  
 
- Supports the following range of approaches to the detection of co-occurring mental health problems: 
 
Approach 1: 
- Use of K10 (SCTT tool). 
 
Approach 2: 
- Use of Mental Health Screening Form. 
 
Both approaches: 
- Identification of a possible mental health disorder triggers:  
i) decision about whether assessment of likely mental health disorder is feasible in-house, or whether referral to 
or consultation with specialist mental health provider is warranted. 
 
ii) mental health assessment. 
 
iii) recording of mental health diagnosis/es alongside substance use disorder diagnosis/es, and 
 
iv) integrated treatment planning around both disorders. 
 
Situations where routine screening should be deferred: 
Routine screening will be deferred when the client is intoxicated, distressed, in pain, in need of emergency 
treatment or acutely psychotic.  
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 Appendix 3: Sample substance use assessment form 
 
Substance use assessment 
Assess each of caffeine / tobacco /alcohol / cannabis / cocaine / amphetamine-type stimulants / sedatives / hallucinogens / 
inhalants / opioids / other drugs (e.g. steroids) 
Tip: Start with legal, ‘innocuous’ substances first. Normalise substance use. Consider multiple sources of information. 
Substance          →  
 Age of first 
use:           
 Age of first 
regular use:           
 Usual method 
of use:           
Ever used  I.V.? 
Age of first 
I.V? 
         
 
Average daily 
use: ($ / std. 
drinks / 
grams / 
bongs /points 
/ hits) 
         
 Days used in 
past 7 days           
 Days used in 
past month           
Date and  
time of last 
use: 
         
 
How long has 
use been 
daily? 
         
Periods of          abstinence:  
Apparent 
stage of 
change: 
          
Stage of change: Precontemplation … Contemplation … Action … Maintenance … Lapse … Relapse 
 
 
 
 
Risk of withdrawal:    Yes    No 
Action in response:  
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
………………….. 
 
ICD 10 substance use diagnosis/es: (also record with mental health diagnosis/es) 
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 ……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
………………….. 
 
Brief intervention:    Yes    No 
Details:  
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………
………………….. 
 
Integrated treatment planning:    Yes    No 
Wholly in-house treatment planned:    Yes    No 
If not, other agencies /workers to be involved: 
……………………………………………………………………………………………………………………
…………………………………………………………………………………………… 
Consent signed:   Yes    No 
Their roles: 
……………………………………………………………………………………………………………………
…………………………………………………………………………………………… 
 
Consent for workers from each agency to communicate and share notes after each contact:    
Yes    No 
 
Where is service to be delivered: (often preferable to all be from the one agency) 
……………………………………………………………………………………………………………………
…………………………………………………………………………………………… 
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Appendix 4: Integrated Treatment Plans 
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Context: 
• Integrated treatment may be provided by a clinician or 
treating team within the one service addressing both a 
person’s substance use and mental health problems. 
• It can also be provided by staff of separate agencies 
working together to agree and implement an individual 
treatment plan. 
 
Dual diagnosis: Key directions 
& priorities for service 
development. 
(2007, Victorian DHS) 
 
 
• Integrated treatment can also occur when clinicians 
from separate agencies agree an individual treatment 
plan addressing both disorders and then provide 
treatment.  
• This integration needs to continue after any acute 
intervention by way of formal interaction and co-
operation between agencies in reassessing and 
treating the client. 
 
 
TIP 42: Substance Abuse 
Treatment for Persons with 
Co-Occurring Disorders 
(SAMHSA, 2005) 
 
 
 
 
• Integration requires the participation of providers 
trained in both substance abuse and mental health 
services to develop a single treatment plan addressing 
both sets of conditions and the continuing formal 
interaction and cooperation of these providers in the 
ongoing reassessment and treatment of the client. 
• The threshold for integration relative to collaboration is 
the shared responsibility for the development and 
implementation of a treatment plan that addresses the 
co-occurring disorders 
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Integrated Treatment Plan (sample proforma) 
Integrated Treatment Plan 
(sample proforma) 
Purpose: Plan and deliver integrated treatment when multiple agencies are involved (when it is not possible for a single agency to provide integrated 
assessment and treatment of both mental health and substance use needs). 
Name:  
John Smith 
Address: 
Beyond the black stump 
AOD agency identifier:   123456 Mental health identifier:   654321 
Consent – has client consented to interagency referral? Yes No Agencies involved:  
- Black Stump Primary Mental Health 
- Black Stump Alcohol & Other Drug Service 
 
Participants involved: (client, carers, workers) 
- John (client) 
- Jane (wife) 
- Jill (Counsellor – Black Stump Primary Mental Health) 
- Jim (Counsellor – Black Stump Alcohol & Other Drug Service) 
Interagency communication: 
AOD & mental health workers agree to communicate  
• In person / per phone / per letter 
• After each client contact     □Yes    □No  
 
• On the ……/………/……. at …………………………… 
 
Need category 
 
Current situation 
 
Identified 
Goals 
 
Strategy / 
Responsibility 
Timing/dates  
Outcome 
Outcome 
date 
 
John aims to drink 
only two nights per 
week 
 
Supervise home-
based alcohol 
withdrawal and 
initial month of 
alcohol abstinence 
(Jim / John / Jane / 
GP)  
Commence 
after next GP 
appointment 
(tomorrow) 
  
 
 
Practice stress 
management 
techniques (John / 
Jane / Jill) 
 
Daily   
 
 
 
 
 
Emotional and 
mental wellbeing 
 
 
 
 
 
In treatment for 
anxiety and 
depression 
associated with 
alcohol dependence 
 
 
 
Reduction in 
symptoms of 
anxiety & 
depression 
Continue CBT 
counselling / 
monitor mental state 
(John / Jill) 
Next 
appointment  
in one week 
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Appendix 5: ICD 10 Substance use disorder 
diagnoses ready reckoner 
 
 
 
Suggestion: print (double-sided) & laminate the following 2 pages as a 
desktop aid to assist mental health clinicians to accurately record co-
occurring substance use disorders
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ICD 10 
Ready Reckoner 
Mental and behavioural disorders due to 
psychoactive substance use 
A tool to assist in the recording of co-
occurring substance use disorders 
diagnoses 
 
ICD 10 – Mental and behavioural disorders due to psychoactive substance use can be found (full-text) at 
http://www3.who.int/icd/vol1htm2003/fr-icd.htm  
Dual diagnosis 
best practice: 
Substance use diagnosis/es are routinely recorded alongside mental health diagnoses 
 
Clinical state 
ICD 10 
Disorders due to psychoactive 
substance use 
.0 
Acute 
intoxication 
.1 
Harmful 
use 
.2 
Dependence 
syndrome 
.3 
Withdrawal 
state 
.4 
Withdrawal 
state with 
delirium 
.5 
Psychotic 
disorder 
.6 
Amnesic 
syndrome 
.7 
Residual and 
late-onset 
psychotic 
disorder 
.8 
Other mental 
and 
behavioural 
disorders 
F10 
ALCOHOL F10.0 F10.1 F10.2 F10.3 F10.4 F10.5 F10.6 F10.7 F10.8 
F11    
OPIOIDS F11.0 F11.1 F11.2 F11.3 F11.4 F11.5 F11.6 F11.7 F11.8 
F12   CANNABINOIDS F12.0 F12.1 F12.2 F12.3 F12.4 F12.5 F12.6 F12.7 F12.8 
F13   
SEDATIVES or 
HYPNOTICS 
F13.0 F13.1 F13.2 F13.3 F13.4 F13.5 F13.6 F13.7 F13.8 
F14   
COCAINE F14.0 F14.1 F14.2 F14.3 F14.4 F14.5 F14.6 F14.7 F14.8 
F15  Other 
STIMULANTS, 
 inc. caffeine 
F15.0 F15.1 F15.2 F15.3 F15.4 F15.5 F15.6 F15.7 F15.8 
F16  
HALLUCINOGENS F16.0 F16.1 F16.2 F16.3 F16.4 F16.5 F16.6 F16.7 F16.8 
F17   
TOBACCO F17.0 F17.1 F17.2 F17.3 F17.4 F17.5 F17.6 F17.7 F17.8 
F18   
volatile SOLVENTS F18.0 F18.1 F18.2 F18.3 F18.4 F18.5 F18.6 F18.7 F18.8 
 
 
 
Substance 
involved 
 
Mental and  
behavioural 
disorders  
due to use  
of ... 
 
 
 
 
F19   
MULTIPLE drugs & 
OTHER substances 
F19.0 F19.1 F19.2 F19.3 F19.4 F19.5 F19.6 F19.7 F19.8 
 
Chapter V ICD 10: ‘This block contains a wide variety of disorders that differ in severity and clinical form but that are all attributable to the use of one or more 
psychoactive substances, which may or may not have been medically prescribed. The third character of the code identifies the substance involved, and the fourth 
character specifies the clinical state. The codes should be used, as required, for each substance specified, but it should be noted that not all fourth-character 
codes are applicable to all substances.’ 
Eastern Hume Dual Diagnosis Service
Clinical states checklists 
 
 Checklist criteria for the various clinical states 
Clinical state Criteria Check 
Disturbances in level of consciousness, cognition, perception, affect or behaviour, or other psycho-
physiological functions and responses 
 
The disturbances are directly related to the acute pharmacological effects of the substance and resolve 
with time, with complete recovery, except where tissue damage or other complications have arisen.  
 
.0 
Acute intoxication 
A condition that follows the 
administration of a 
psychoactive substance 
resulting in: 
Complications may include trauma, inhalation of vomitus, delirium, coma, convulsions and other medical  
complications. The nature of these complications depends on the pharmacological class of substance 
and mode of administration. 
 
A pattern of psychoactive substance use that is causing damage to health.  
The damage may be physical (e.g. hepatitis from injecting) or  .1 Harmful use 
mental (e.g. episodes of depressive disorder secondary to heavy alcohol consumption).  
 
a strong desire to take the drug  
difficulties in controlling its use  
persisting in its use despite harmful consequences  
a higher priority given to drug use than to other activities and obligations  
increased tolerance  
A cluster of behavioural, 
cognitive and physiological 
.2 phenomena that develop 
Dependence syndrome after repeated substance 
 use and typically 
include ... sometimes, a physical withdrawal state.  
 
A group of symptoms of variable clustering and severity occurring on absolute or relative withdrawal of a 
psychoactive substance after persistent use of that substance. 
 
Onset and course of the withdrawal state are time-limited and are related to the type of substance and 
dose being used immediately before cessation or reduction of use. 
 
.3 
Withdrawal 
state 
The withdrawal state may be complicated by convulsions.  
 
.4 
Withdrawal state 
with delirium 
A condition where the withdrawal state (as defined in .3 above) is complicated by delirium.   
Convulsions may also occur.  
 
Not explained on the basis of acute intoxication alone.  
Does not form part of a withdrawal state.  .5 
hallucinations (typically auditory, but often in more than one sensory modality)  Psychotic 
perceptual distortions  
 disorder 
delusions (often of a paranoid or persecutory nature)  
psychomotor disturbances (excitement or stupor)  
The disorder is 
characterised by 
… 
 
abnormal affect, which may range from intense fear to ecstasy.  
The sensorium is usually clear but some degree of clouding of consciousness, though not severe 
confusion, may be present. 
 
A cluster of psychotic 
phenomena that occur 
during or following 
psychoactive substance use 
 
Excludes: alcohol or other substance-induced residual and late-onset psychotic disorder.  
 
Immediate recall is usually preserved and recent memory is characteristically more disturbed than  
remote memory.  
Disturbances of time sense and ordering of events are usually evident, as are difficulties in learning new 
material. 
 
Confabulation may be marked but is not invariably present.  
.6 
Amnesic syndrome 
 
A syndrome associated with 
chronic prominent 
impairment of recent and 
remote memory 
Other cognitive functions are usually relatively well preserved and amnesic defects are out of proportion  
to other disturbances. 
 
Onset of the disorder should be directly related to the use of the 
psychoactive substance. 
 
Cases in which initial onset of the state occurs later than episode(s) 
of such substance use should be coded here only where clear and 
strong evidence is available to attribute the state to the residual effect 
of the psychoactive substance. 
 
A disorder in which alcohol- or 
psychoactive substance-
induced changes of cognition, 
affect, personality or behaviour 
persist beyond the period 
during which a direct 
psychoactive substance-related 
effect might reasonably be 
assumed to be operating. 
.7 
Residual & late-onset 
psychotic disorder Flashbacks may be distinguished from psychotic state partly by their 
episodic nature, frequently of very short duration and by their 
duplication of previous alcohol- or other psychoactive substance-
related experiences. 
 
 
 
.9 .8 
Other mental and behavioural disorders Unspecified mental and behavioural disorder 
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 Appendix 6: Victorian Dual Diagnosis Teams – 
Contacts:  
VDDI Education and Training Unit 
VDDI Education & Training Unit (State-wide) 
St Vincent's Hospital  
Nicholson St  
(PO Box 2900) 
Fitzroy VIC 3065  
T: 03 9288 2383  
Metropolitan Lead Agencies 
Metro: Central East, Outer East  Addiction Consulting  
Rural: Eastern Hume Eastern Dual Diagnosis Team 
Ground Floor, 43 Carrington Rd 
Box Hill VIC 3128 
T: 03 9843 1277 
Metro: Yarra, Boroondara, Banyule, Nilumbik  Northern NEXUS 
Rural: Loddon and Northern Mallee St Vincent’s Hospital 
P.O. Box 2900 
Fitzroy VIC 3065 
T: 03 9288 3824 
Metro: Port Phillip, Kingston, Bayside, Greater 
Dandenong, Casey, Cardinia, Mornington 
Peninsula, Frankston,  
Southern Dual Diagnosis Service 
c/- SEADS 
2/229 Thomas St, 
Dandenong VIC 3175 parts of Monash, Glen Eira, Stonington 
Rural: Gippsland and La Trobe Valley T: 03 8792 2330 
Metro: Maribyrnong, Wyndham, Brimbank, 
Hobsons Bay, Melton, Moonee Valley, Moreland, 
Hume, Darebin, Melbourne City, and Whittlesea 
SUMITT (Western ) 
3-7 Eleanor St, 
Footscray VIC 3011 
Rural: Grampians, Barwon, South West and 
Goulburn Valley 
T: 03 8345 6682 
VDDI Rural Services 
Barwon Gippsland 
Barwon Health, Drug Treatment Service Gippsland Dual Diagnosis 
40 Little Malop St Box 424, Traralgon VIC 3844 
Geelong VIC 3220 T: 03 5128 0009 
T: 03 5273 4000 
Glenelg Goulburn 
South West Health Care  - Monash St, Shepparton VIC 3630 
Lava St T: 03 5832 2111 
(PO Box 197) - PO Box 800, Seymour VIC 3660 
Warrnambool VIC 3280 T: 03 5735 0333 
T: 03 5561 3813 
Grampians Loddon 
Grampians Psychiatric Services Bendigo Health Care Group 
P.O Box 577 PO Box 126, Bendigo 3550 VIC  
Ballarat VIC 3356 T: 03 5454 7608
T: 03 5320 4100 
Eastern Hume Northern Mallee 
Eastern Hume Dual Diagnosis Service Ramsay Health, Mildura Base Hospital 
Box 1225  107 Pine Ave, Mildura 3500 VIC  
Wangaratta VIC 3677  T: 03 5018 7917 
T: 03 5722 2677  
www.dualdiagnosis.org.au  
 
 Page 45
